Company intelligence / Profile preview

CIS BIOPHARMA

Bubendorf, Basel-Landschaft, Switzerlandcisbiopharma.com ↗

Ownership: Private
Development stage: Other

Overview

CIS BIOPHARMA has demonstrated preclinical efficacy of its lead ADC program CBO‑001 against SCLC. Their radioligand targeting L1CAM has shown strong activity in ovarian cancer xenograft models. Comparative preclinical data suggest best-in-class potential for their programs. Clinical trials are expected to begin in 2025

Therapeutic areas: Oncology
Modalities: Antibody-drug conjugateRadiopharmaceuticalMonoclonal antibodyNanobody
Industry: Biotech

Drug pipeline

3 assets

CBO-002

Preclinical

2 more assets in the full pipeline.

Request access →

Partnerships

Collaborations with patient organizations, clinics, physicians, scientists and financial partners are mentioned but no specific major pharma partnerships disclosed yet

Beyond the preview

Go deeper on CIS BIOPHARMA.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on CIS BIOPHARMA.

Explore the full profile